Description: Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pantoprazole sodium products, etc. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding drugs, analgesics, and other fields. The company was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co., Ltd. in September 2021. Sailong Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Zhuhai, China.
Home Page: www.sailong.cn
Everbright International Trade Center
Zhuhai,
519015
China
Phone:
86 75 6388 2955
Officers
| Name | Title |
|---|---|
| Ms. Zhang Xu | Board Sec., Deputy GM & Director |
| Mr. Jian Feng Li | Deputy GM & Director |
Exchange: SHE
Country: CN
Currency: Renminbi (¥)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.9031 |
| Price-to-Sales TTM: | 11.0653 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 405 |